Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
$30.24
$0.01(0.04%)
At close: 4:00 PM EST
$30.24
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$13.30 - $30.78
Previous CloseN/A
Volume37.78K
Average Volume (3M)737.59K
Market Cap
$1.81B
Enterprise Value$1.70B
Total Cash (Recent Filing)$462.62M
Total Debt (Recent Filing)$399.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 20, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding59,800,407
10 Day Avg. Volume746,769
30 Day Avg. Volume737,591
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.87K
Enterprise Value/Ebitda-14.82
Forecast
1Y Price Target
$37.67Price Target Upside24.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.05
Revenue Forecast (FY)$10.00K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly clinical results showed durable major molecular responses and meaningful molecular remissions in heavily pretreated chronic myeloid leukemia patients, supporting activity in a difficult-to-treat population.
Development Pathway And Analyst SentimentCompany intends to advance ELVN-001 into a pivotal Phase 3 trial and an analyst has assigned a Buy rating, signaling confidence as the program moves toward registrational study and additional data releases.
Mechanism And Market PositioningELVN-001 targets the ATP-binding pocket on the cancer protein, enabling treatment of patients who failed therapies that bind the other pocket and preserving opportunity in second-line and later patient groups.
Bears Say
Comparative Efficacy BenchmarkA competing BCR-ABL1 inhibitor reported higher early response rates, creating a benchmark that may challenge perceptions of ELVN-001's efficacy advantage in initial comparisons.
Competitive Pressure From Similar-mechanism EntrantA competitor developing a therapy with the same mechanism is positioned to compete in earlier treatment lines, which could reduce addressable patients and create adoption and pricing pressure.
Data Maturity RiskManagement cautions that immature response analyses can overstate response rates because patients without sufficient follow-up may be excluded unless a response is recorded, raising the risk that early outcomes may change as data matures.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $30.78 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.81B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 69 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 03, 2026. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.095.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 59,800,407 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went up 4.278%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (24.57% Upside)
$37.67 (24.57% Upside)
Blogger Sentiment
Neutral
ELVN Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $295.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 4.6%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.57%
12-Months-Change
Fundamentals
Return on Equity
-24.22%
Trailing 12-Months
Asset Growth
46.20%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$37.67
▲(24.57% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―